Why the study?
Does dabigatran etexilate increase thromboembolic events compared with phenprocoumon in patients with a left ventricular assist device?
Does dabigatran etexilate increase thromboembolic events compared with phenprocoumon in patients with a left ventricular assist device?
Answers are grounded in this paper and cite their sources.
This letter from the manufacturer of dabigatran disputes the dosing rationale and monitoring claims made in a pilot trial of LVAD patients.
HomeCirculation: Heart FailureVol. 10, No. 10Letter by Heinrich-Nols and Kreuzer Regarding Article, "Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial" Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLetter by Heinrich-Nols and Kreuzer Regarding Article, "Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial" Jutta Heinrich-Nols, MD and Jörg Kreuzer, MD Jutta Heinrich-NolsJutta Heinrich-Nols From Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany. and Jörg KreuzerJörg Kreuzer From Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany. Originally published13 Oct 2017https://doi.org/10.1161/CIRCHEARTFAILURE.117.004273Circulation: Heart Failure. 2017;10:e004273We thank Andreas et al1 for publishing the results of their pilot study comparing dabigatran etexilate with phenprocoumon in patients with a left ventricular assist device.The authors selected a dabigatran dose of 110 mg twice daily (BID) for patients with normal renal function (creatinine clearance >80 mL/min; n=2) and 75 mg BID for patients with impaired renal function (creatinine clearance 30–80 mL/min; n=6) and observed an excess of thromboembolic events with dabigatran compared with phenprocoumon. They state that "The dose administered…was in accordance with the recommended dose for atrial fibrillation as of 2010 and based on the RE-LY study results" and also that "Dabigatran dosages…adhered to the recommended dosage guidelines for approved indications in the year 2010, such as atrial fibrillation and deep vein thrombosis." This is incorrect information.In 2010, there was no approved indication for treatment of deep vein thrombosis. The dabigatran doses evaluated in RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) were 150 and 110 mg BID, and both are approved for stroke prevention in patients with atrial fibrillation, except in the United States, where only 150 mg BID is approved for all patients with creatinine clearance >30 mL/min and 75 mg BID is recommended for a subset of patients. The 110 mg BID dose is approved in this indication only outside the United States for a subset of patients (>80 years, cotreatment with verapamil), or based on an individual assessment of the thromboembolic and bleeding risks (eg, patients with moderate renal impairment).The authors acknowledge that in 2013 they reviewed the results of the RE-ALIGN study (Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients After Heart Valve Replacement) of dabigatran in heart valve replacement patients but decided to continue their pilot trial owing to the lack of data in patients with left ventricular assist device. RE-ALIGN tested higher dabigatran doses (150, 220, and 300 mg BID, according to renal function), yet was stopped early because of an excess of thromboembolic and bleeding events in the dabigatran group. In 2013, the contraindication for prosthetic heart valves was included in the dabigatran label. As the need for anticoagulation in left ventricular assist device patients is comparable to the thrombogenic situation of patients with a prosthetic heart valve, where the contact pathway plays an important role in coagulation, it seems that the label update and discussion in the literature were not considered.We also highlight the erroneous assertion that the "Current state of research indicates regular drug monitoring of dabigatran to confirm the anticoagulant effects via …assay[s]". The supporting reference is not a primary research article but an opinion piece and is accompanied by a strong rebuttal from the coordinating investigator of the RE-LY trial.2 The statement disregards the outcomes of the European Medicines Agency workshop published at the end of 2015.3 Neither the label of dabigatran nor treatment guidelines include a recommendation for regular drug monitoring.4,5Under Sources of Funding, the article states that "Study medication (dabigatran etexilate) was provided by Boehringer Ingelheim Pharma GmbH and Co KG", which is not correct. Boehringer Ingelheim neither funded the trial nor provided trial supplies or other financial or intellectual support.DisclosuresDrs Heinrich-Nols and Kreuzer are employees of Boehringer Ingelheim (significant).FootnotesCirc Heart Fail is available at http://circheartfailure.ahajournals.org.References1. Andreas M, Moayedifar R, Wieselthaler G, Wolzt M, Riebandt J, Haberl T, Angleitner P, Schlöglhofer T, Wiedemann D, Schima H, Laufer G, Zimpfer D. Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients: a randomized controlled pilot trial.Circ Heart Fail. 2017; 10:e003709. doi: 10.1161/CIRCHEARTFAILURE.116.003709.LinkGoogle Scholar2. Connolly S. Efficacy, Safety and Optimal Dosing Of Dabigatran – A Commentary on the BMJ Articles on Dabigatran.BMJ2014; 349:g4517. doi: 10.1136/bmj.g4517.Google Scholar3. European Medicines Agency. Workshop on the Role of Pharmacokinetic and Pharmacodynamic Measurements in the Use of Direct Oral Anticoagulants.Workshop Proceedings. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2015/08/event_detail_001181.jsp&mid=WC0b01ac058004d5c3. Accessed November 1, 2015.Google Scholar4. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.Eur Heart J. 2016; 37:2893–2962. doi: 10.1093/eurheartj/ehw210.CrossrefMedlineGoogle Scholar5. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Circulation. 2014; 130:e199–e267. doi: 10.1161/CIR.0000000000000041.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails October 2017Vol 10, Issue 10 Advertisement Article InformationMetrics © 2017 American Heart Association, Inc.https://doi.org/10.1161/CIRCHEARTFAILURE.117.004273PMID: 29030373 Originally publishedOctober 13, 2017 PDF download Advertisement SubjectsAnticoagulants
No takes yet. Share an insight, caveat, or question.
Heinrich-Nols et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: